# Aqua Medical L.L.C.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aqua-medical-l-l-c

- Industry: Biotechnology
- Headquarters: Pleasanton, US
- Website: www.aquaendoscopy.com
- Total disclosed funding: $8.2M
- Latest round: Series B (Sep 23, 2026)
- Investors on record: 4

## About

Aqua Medical L.L.C. specializes in innovative medical therapies aimed at improving glycemic control for type 2 diabetes patients, utilizing advanced technology to enhance treatment options and patient outcomes.Aqua Medical L.L.C. was founded in 2016 and is headquartered in Santa Ana, US. The company focuses on developing technology for diabetes management, specifically through its Radio Frequency Vapor Ablation (RFVA) System. Virender Sharma is the founder, while Lloyd Mencinger serves as CEO. In September 2020, the company raised USD 8.2 mn in Series A funding, with ShangBay Capital leading the round. The total amount raised to date is USD 8.2 mn, with three notable deals completed, showing a commitment to advancing diabetes treatment technologies.Aqua Medical specializes in innovative medical therapies focused on improving glycemic control for patients with type 2 diabetes through its core product: the Radio Frequency Vapor Ablation (RFVA) System. This platform technology utilizes heated water vapor generated by a radiofrequency generator, delivered via endoscope to non-surgically ablate the duodenal mucosa. The RFVA System aims to interrupt the metabolic cycle of type 2 diabetes by reducing insulin dependency and promoting weight management, primarily targeting the U.S. market, with potential applications worldwide.Aqua Medical generates revenue through partnerships and direct sales of its FDA-cleared RFVA System to healthcare providers. Institutions typically acquire the system for outpatient procedures to treat individuals with type 2 diabetes. The company engages with hospitals and clinics under contracted agreements, ensuring ongoing access to its technology, while pricing plans are tailored to institutional clients, aligning costs with the adoption of the RFVA System for managing diabetes effectively.Aqua Medical plans to utilize its recent funding of USD 8.2 mn raised in September 2020 to support the development of new products and expand its market presence. The company aims to launch additional therapeutic solutions designed for diabetes management in the near future, while strategically targeting expansion into European and Asian markets by 2023. This aligns with Aqua Medical's goal of addressing the rising global prevalence of type 2 diabetes through enhanced treatment options.

## Funding rounds

- Series B, Sep 23, 2026 — Relevance Ventures
- Series A, Sep 1, 2020, $8.2M — ForMED Ventures, ShangBay Capital, Ithaka Partners

## Investors

- ForMED Ventures (https://capitalatlas.ai/funds/formed-ventures) — Series A
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series A
- Ithaka Partners (https://capitalatlas.ai/funds/ithaka-partners) — Series A
- Relevance Ventures (https://capitalatlas.ai/funds/relevance-ventures) — Series B